



Supplementary Figure 1. Trial design of the PERFECT study.

Neoadjuvant chemoradiotherapy according to the CROSS regimen was combined with atezolizumab in week one and week four on the day of intravenous chemotherapy administration. Thereafter, atezolizumab was given as monotherapy in week 7, 10 and 13. Surgery was performed between week 14 and 16. Abbreviations: ICI = Immune checkpoint inhibitor; nCRT = neoadjuvant chemoradiotherapy.